Evidence map›Paper›PMID 36186601›Full record

ArticleFrontiers in chemistry2022

Design, synthesis and biological evaluation of 9-aryl-5

Lingyu Shi, Shanbo Yang, Jing Chang, Yujing Zhang, Wenjing Liu, Jun Zeng, Jingsen Meng, Renshuai Zhang, Chao Wang, Dongming Xing

Abstract read
In one paragraph

Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lingyu ShiCancer Institute, The Affiliated Hospital of Qingdao University and School of Basic Medicine, Qingdao University, Qingdao, China.
Shanbo YangCancer Institute, The Affiliated Hospital of Qingdao University and School of Basic Medicine, Qingdao University, Qingdao, China.
Jing ChangCancer Institute, The Affiliated Hospital of Qingdao University and School of Basic Medicine, Qingdao University, Qingdao, China.
Yujing ZhangThe Affiliated Cardiovascular Hospital of Qingdao University, Qingdao University, Qingdao, China.
Wenjing LiuCancer Institute, The Affiliated Hospital of Qingdao University and School of Basic Medicine, Qingdao University, Qingdao, China.
Jun ZengCancer Institute, The Affiliated Hospital of Qingdao University and School of Basic Medicine, Qingdao University, Qingdao, China.
Jingsen MengCancer Institute, The Affiliated Hospital of Qingdao University and School of Basic Medicine, Qingdao University, Qingdao, China.
Renshuai ZhangCancer Institute, The Affiliated Hospital of Qingdao University and School of Basic Medicine, Qingdao University, Qingdao, China.
Chao WangCancer Institute, The Affiliated Hospital of Qingdao University and School of Basic Medicine, Qingdao University, Qingdao, China.
Dongming XingCancer Institute, The Affiliated Hospital of Qingdao University and School of Basic Medicine, Qingdao University, Qingdao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of new 9-aryl-5

Indexed as

antitumor activitymolecular dockingpyrido[4,3-b]indoletubulintubulin polymerization inhibitors

Identifiers

PMID36186601
PMCPMC9520531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.